Evidence map›Paper›PMID 28209923›Full record

ArticleOncotarget2017

Novel involvement of RhebL1 in sphingosylphosphorylcholine-induced keratin phosphorylation and reorganization: Binding to and activation of AKT1.

Hyun Ji Kim, Hyun Jung Byun, Mi Kyung Park, Eun Ji Kim, Gyeoung Jin Kang, Chang Hoon Lee

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Hyun Ji KimCollege of Pharmacy, Dongguk University, Seoul 100-715, Republic of Korea.
Hyun Jung ByunCollege of Pharmacy, Dongguk University, Seoul 100-715, Republic of Korea.
Mi Kyung ParkCollege of Pharmacy, Dongguk University, Seoul 100-715, Republic of Korea.
Eun Ji KimCollege of Pharmacy, Dongguk University, Seoul 100-715, Republic of Korea.
Gyeoung Jin KangCollege of Pharmacy, Dongguk University, Seoul 100-715, Republic of Korea.
Chang Hoon LeeCollege of Pharmacy, Dongguk University, Seoul 100-715, Republic of Korea.
Dongguk University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sphingosylphosphorylcholine induces keratin phosphorylation and reorganization, and increases viscoelasticity of metastatic cancer cells such as PANC-1 cells. However, the mechanism involved in sphingosylphosphorylcholine-induced keratin phosphorylation and reorganization is largely unknown. Sphingosylphosphorylcholine dose- and time-dependently induces the expression of RhebL1. The involvement of RhebL1 in sphingosylphosphorylcholine-induced events including keratin 8 (K8) phosphorylation, reorganization, migration and invasion was examined. Gene silencing of RhebL1 suppressed the sphingosylphosphorylcholine-induced events and overexpression of RhebL1 enhanced those events even without sphingosylphosphorylcholine treatment. We examined whether the G protein function of RhebL1 induces K8 phosphorylation using constitutively active RhebL1Q64L and dominant negative RhebL1D60K. G protein activity of RhebL1 is involved in sphingosylphosphorylcholine-induced K8 phosphorylation. We found that RhebL1 binds and activates AKT1. G protein activity of RhebL1 is involved in the binding and activation of AKT1. MK2206 (AKT inhibitor) and gene silencing of AKT1 inhibited the sphingosylphosphorylcholine-induced events, whereas overexpression of activated-AKT1 induced K8 phosphorylation, reorganization, migration and invasion even without sphingosylphosphorylcholine treatment.The collective results indicate that RhebL1 is involved in sphingosylphosphorylcholine-induced events in A549 lung cancer cells via binding to AKT1 leading to activation of it. These results suggest that suppression of RhebL1 or inhibition of RhebL1's binding to AKT1 might be a novel way that prevents changes in the physical properties of metastatic cancer cells.

Indexed as

ApoptosisBiomarkers, TumorCell ProliferationGene Expression Regulation, NeoplasticGTP-Binding ProteinsHumansKeratinsLung NeoplasmsNeoplasm StagingPhosphorylationPhosphorylcholinePrognosisProto-Oncogene Proteins c-aktras ProteinsSphingosineSurvival RateBiomarkers, TumorGTP-Binding ProteinsKeratinsPhosphorylcholineProto-Oncogene Proteins c-aktras ProteinsRHEBL1 protein, humanSphingosinesphingosine phosphorylcholineAKT1keratin reorganizationmigrationRhebL1sphingosylphosphorylcholine

Identifiers

PMID28209923
PMCPMC5400551
OpenAlexW2588557080

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.